Injection, galsulfase, 1 mg
Enzyme Replacement Therapy
Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.
NAGLAZYME is an Enzyme Replacement Therapy drug manufactured by Biomarin Pharma and administered via the Intravenous route of administration. The J Code: J1458 is aligned to the drug NAGLAZYME.
NAGLAZYME is an enzyme replacement therapy commonly used to treat Mucopolysaccharidosis IV, also known as Maroteaux-Lamy syndrome. It works by providing the patient with exogenous hydrolytic lysomomal glucosaminoglycan (GAG)-specific enzyme that is taken up into the lysosomes, allowing the body to catabolize the GAG that is built up in the organs and tissues of the patient. NAGLAZYME (J1458) is frequently used for treatment with pediatric patients. Patient assistance for this medication can be found through the BioMarin program.
January 1, 2007
January 1, 2023